Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is in a strong financial position with a solid cash balance to support its sales team expansion and R&D initiatives. The increase in pharmacy new patient starts is a positive sign for the company's financial performance in the coming quarters and years. With the company's positive clinical trial results and upcoming product launches, we believe Beta Bionics has a compelling investment opportunity with a potential for market share gains and revenue growth.

Bears say

Beta Bionics is facing operational and market risks amidst a slowdown in its net promoter score and a recent FDA warning letter. Despite an optimistic outlook for the iLet Bionic Pancreas and potential growth in the pharmacy channel and Type 2 diabetes market, the company's stock has been on a downtrend due to the NPS miss and regulatory uncertainties. With a current valuation at a discount to its peer group and potential for re-acceleration in NPS momentum and progress on its new patch pump, the stock offers favorable risk-reward.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.